I didn't say they wouldn't use embryonic stem cells. Only that it does not appear that they are, based on current and past agreements.
As I said, I also don't think the prospects of "opening" the embryonic stem cell market supports a 255% gain on almost 10x average volume. There is something specific (merger, partnership, etc.) that is brewing IMO, that has sparked the sudden interest.
Here's to a profitable trade for all of us.
Murocman